Skip to main content
Premium Trial:

Request an Annual Quote

By Foundation Medicine

Perspective: How Biopharma Can Navigate EU IVDR to Keep Clinical Studies on Track

With advance planning and a diagnostics partner with demonstrated regulatory expertise, it is possible to navigate EU IVDR requirements with confidence and keep clinical trial timelines on track.

By Illumina

Baylor Genetics Prepares for a ‘Genome World’ With Explainable AI-Powered Variant Interpretation

Explainable artificial intelligence, or XAI, is enabling Baylor Genetics to hasten and scale up clinical whole-genome sequencing while testing becomes more accessible and evidence for its utility grows.

By Illumina

Genomic Medicine Calls for AI That Can Explain Itself, Illumina Says

Artificial intelligence models that can explicitly demonstrate their logic and expose potential biases, known as explainable AI, or XAI, are necessary for medical institutions to make healthcare decisions with increased confidence, according to Illumina. 

By VolitionRx

Perspective: The Epigenetic Keys to Unlocking the Full Potential of Immunotherapy

Epigenetics is the key to unlocking the full potential of cancer therapy, including immunotherapies, by revealing deep insights into how the body reacts and responds to medication.

By Revvity

Advancements in Alzheimer's Treatment Unveil New Diagnostic Applications

rev_logo_rgb_black 3.jpg

As more Alzheimer’s disease treatment options become available, the field of diagnostics is rapidly evolving to adapt to new demands.

By Foundation Medicine

Foundation Medicine Unveils Strategy to Support Cancer CDx Filings with RWE from Clinico-Genomic Database

Foundation Medicine and Flatiron Health are introducing a novel capability for supporting companion diagnostic regulatory filings with real-world data from the Flatiron Health-Foundation Medicine Clinico-Genomic Database.

By AstraZeneca

Perspective: Patients with Resectable Non-Small Cell Lung Cancer (NSCLC) – Your Referral Is As Mighty As Your Scalpel

Comprehensive biomarker testing can be integral in determining a multi-disciplinary team’s approach to managing their patient’s cancer diagnosis.

By Oxford BioDynamics

Q&A: Analyzing Blood, Not the Tumor: A Novel Test for Personalized Cancer Immunotherapy

Genkin 2.png

In this Q&A, Igor Genkin, medical director at Salem Regional Cancer Center, discusses a minimally invasive test detecting 3D genomic markers that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to any immune checkpoint inhibitors.

By Revvity

Perspective: Data-Driven Strategies Streamline Cell Therapy Development

rev_logo_rgb_black 3.jpg

Cell therapy has the potential to create highly innovative, life-changing medicines with never-before-achieved therapeutic and curative potential, but fragmented processes and inefficient data management can slow down cell therapy pipelines.

By Kinnate Biopharma

BRAF Class II and NRAS-Targeting Drug Shows Promising Efficacy, Safety, and Tolerability in Early Phase I Data

The agent could potentially contribute to meeting the significant medical need posed by patients whose tumors harbor these alterations.